Danaher Stock

$199.03

0.21% yesterday

NYSE, Sep 04, 10:00 pm CET

ISIN

US2358511028

Symbol

DHR

Reports

Quarter | Annual

Index

NYSE Composite, S&P 500

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Life Sciences Tools & Services

Overview Dividends Analysts Charts News Strategies

Danaher Stock price

$199.03

+24.78 14.22% 5Y

NYSE, Closing price Thu, Sep 04 2025

-0.41 0.21%

ISIN

US2358511028

Symbol

DHR

Reports

Quarter | Annual

Index

NYSE Composite, S&P 500

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Life Sciences Tools & Services

Key metrics

Basic

Market capitalization

$142.5b

Enterprise Value

$156.9b

Net debt

$14.4b

Cash

$3.0b

Shares outstanding

715.9m

Valuation (TTM | estimate)

P/E

42.0 | 25.3

P/S

5.9 | 5.7

EV/Sales

6.5 | 6.3

EV/FCF

32.3

P/B

2.7

Dividends

DPS

$1.08

Yield 1Y | 5Y

0.5% | 0.4%

Growth 1Y | 5Y

9.2% | 12.4%

Payout 1Y | 3Y

20.4% | 13.9%

Increased

11 Years

Financials (TTM | estimate)

Revenue

$24.0b | $24.9b

EBITDA

$7.1b | $7.7b

EBIT

$4.8b | $7.1b

Net Income

$3.4b | $5.6b

Free Cash Flow

$4.9b

Growth (TTM | estimate)

Revenue

1.9% | 4.5%

EBITDA

-1.8% | 1.5%

EBIT

-6.0% | 35.3%

Net Income

-18.8% | 44.2%

Free Cash Flow

-4.7%

Financial Health

Equity Ratio

63.9%

Return on Equity

7.9%

ROCE

6.4%

ROIC

5.3%

Debt/Equity

0.3

EPS

$4.7

FCF per Share

$6.8

Short interest

1.5%

Employees

62k

Rev per Employee

$390.0k

As a Free StocksGuide user, you can view scores for all 7,003 stocks worldwide.

Get Started for Free Today

Danaher Stock Analysis

Unlock Scores for Free

??

30 Analysts have issued a Danaher forecast:

27x Buy

90%

More details on Analyst Estimates Including Price Targets

30 Analysts have issued a Danaher forecast:

Buy

90%

Hold

10%

Analyst Estimates with Stock Price Targets

Financial data from Danaher

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Jun '25		+/- %
Revenue	24,013 24,013	2% 2% 100%
- Direct Costs	9,673 9,673	1% 1% 40%
Gross Profit	14,340 14,340	2% 2% 60%
- Selling and Administrative Expenses	7,980 7,980	8% 8% 33%
- Research and Development Expense	1,607 1,607	5% 5% 7%
EBITDA	7,141 7,141	2% 2% 30%
- Depreciation and Amortization	2,388 2,388	8% 8% 10%
EBIT (Operating Income) EBIT	4,753 4,753	6% 6% 20%
Net Profit	3,413 3,413	19% 19% 14%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Danaher Stock News

Negative

Seeking Alpha

●

8 days ago

mRNA Biotechs - Long-Term Value Risks Abound

mRNA vaccine companies are overhyped post-pandemic, facing scientific, operational, and regulatory headwinds that limit long-term investment appeal. Scientific and business risks, including delivery challenges and limited efficacy for cancer and infectious diseases, make mRNA-focused biotechs unattractive compared to broader biotech opportunities. Investors seeking exposure should consider 'pic...

Neutral

The Motley Fool

●

23 days ago

iA Global Buys the Dip in Danaher's Stock Price

On Aug. 5, iA Global Asset Management Inc. disclosed buying 301,028 shares of Danaher (DHR 1.02%), valued at approximately $58.43 million in Q2 2025.

Neutral

Business Wire

●

24 days ago

EQUITY ALERT: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Danaher Corporation – DHR

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces it is investigating potential breaches of fiduciary duties by the directors and officers of Danaher Corporation (NYSE: DHR). If you currently own shares of Danaher stock, please visit the firm's website at https://rosenlegal.com/submit-form/?case_id=17717 for more information. You may also contact Phillip Ki...

More Danaher News

Company Profile

Danaher Corp. operates as a medical company, which designs, manufactures, and markets professional, medical, industrial and commercial products and services. It operates through the following segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines. The Diagnostics segment comprises of analytical instruments, reagents, consumables, software, and services that hospitals, physician's offices, reference laboratories, and other critical care settings use to diagnose disease and make treatment decisions. The Environmental & Applied Solution segment offers products and services that help protect important resources and keep global food and water supplies safe. The company was founded by Steven M. Rales and Mitchell P. Rales in 1969 and is headquartered in Washington, DC.

Head office	United States
CEO	Rainer Blair
Employees	62,000
Founded	1984
Website	www.danaher.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now